Initial clinical experience with a rationally designed, genetically engineered recombinant human hemoglobin.
Shoemaker
S A
SA
Somatogen, Inc., Boulder, CO 80301.
Gerber
M J
MJ
Evans
G L
GL
Archer-Paik
L E
LE
Scoggin
C H
CH
D000210:Acute-Phase Reaction / Q000209:etiology; D000818:Animals; D001802:Blood Substitutes / Q000009:adverse effects / Q000302:isolation & purification* / Q000627:therapeutic use*; D015195:Drug Design; D006454:Hemoglobins / Q000009:adverse effects / Q000235:genetics* / Q000627:therapeutic use*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D010100:Oxygen / Q000378:metabolism; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use
D001802:Blood Substitutes; D006454:Hemoglobins; D011994:Recombinant Proteins; D010100:Oxygen